Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2021
Price :
$35
*
At a glance
- Drugs JNJ 55920839 (Primary) ; JNJ 55920839 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 12 Oct 2020 Results assessing pharmacokinetics and pharmacodynamics of JNJ-55920839 published in the Clinical Drug Investigation
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Planned End Date changed from 19 Sep 2018 to 1 Sep 2018.